Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise

Thromb Haemost. 1992 Nov 10;68(5):550-5.

Abstract

The effects of heparin (5,000 IU i.v.) and the low molecular weight heparinoid Org 10172 (Orgaran) (3,250 anti-Xa units i.v.) on components of the fibrinolytic system were studied in two double-blind, randomised, placebo-controlled, cross-over trials using healthy subjects. In study A (n = 6) the effects were studied during rest and standardized exercise and in study B (n = 6) during a low dose infusion of recombinant tissue-type plasminogen activator (rt-PA; 80 micrograms over 16 min). At rest, heparin and Org 10172 did not influence the plasma concentrations of endogenous t-PA antigen and activity, urokinase-type PA (u-PA) antigen, plasmin activatable pro-urokinase (scu-PA), active urokinase (tcu-PA) and plasminogen activator inhibitor-1 (PAI-1) antigen. Recombinant t-PA antigen and activity during rt-PA infusion were also not affected. During exercise, neither heparin nor Org 10172 influenced the area under the curve (AUC) of t-PA and u-PA antigen and t-PA activity when compared with placebo. Unexpectedly, after heparin the AUC of t-PA activity was 49% larger (range +19 to +245%) than after Org 10172 (p < 0.05). The last difference was considered spurious, scu-PA, tcu-PA and PAI-1 antigen levels at 2 min after termination of exercise were unaffected by both compounds (p > 0.05). Sulphated polysaccharides do not increase fibrinolytic activity of the plasma by changing the concentrations of the components of the fibrinolytic system.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Chondroitin Sulfates*
  • Dermatan Sulfate*
  • Double-Blind Method
  • Exercise / physiology
  • Fibrinolysis / drug effects*
  • Fibrinolysis / physiology
  • Fibrinolytic Agents / pharmacology
  • Glycosaminoglycans / pharmacology*
  • Heparin / pharmacology*
  • Heparinoids / pharmacology*
  • Heparitin Sulfate*
  • Humans
  • Male
  • Plasminogen Activator Inhibitor 1 / blood
  • Recombinant Proteins
  • Tissue Plasminogen Activator / blood
  • Urokinase-Type Plasminogen Activator / blood

Substances

  • Fibrinolytic Agents
  • Glycosaminoglycans
  • Heparinoids
  • Plasminogen Activator Inhibitor 1
  • Recombinant Proteins
  • Dermatan Sulfate
  • Heparin
  • Chondroitin Sulfates
  • Heparitin Sulfate
  • danaparoid
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator
  • saruplase